ArticleUrolithiasis2025
Comprehensive Mendelian randomization analysis and experimental investigation identifies the causal relationship between immunity and kidney stone disease.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study investigated the causal relationship between immunity and kidney stone disease (KSD) by utilizing a Mendelian Randomization (MR) framework. We conducted a proteome-wide analysis to identify proteins associated with kidney stone disease risk using data from 4907 plasma proteins. Additionally, genetic instruments were employed to assess the impact of immune traits, including circulating inflammatory proteins, immune cell traits, immune-mediated diseases, and mRNA expression on kidney stone disease. Immunofluorescence staining was also performed to confirm gene expression patterns in kidney tissues affected by Randall's Plaque (RP). The results of the inverse variable weighting method showed that 174 plasma proteins were positively associated with KSD [ P < 0.05, odds ratio (OR) > 1]; 48 plasma proteins were negatively associated with KSD (P < 0.05, OR < 1). Subsequently, GO and KEGG analysis showed significant enrichment in immune pathways. Notably, elevated levels of inflammatory proteins such as CCL19 (OR per SD, 1.084; 95% CI = 1.006-1.167), OSM (OR per SD, 1.120; 95% CI = 1.023-1.227), and FGF5 (OR per SD, 1.077; 95% CI = 1.020-1.136) were associated with an increased risk of KSD. We also observed positive associations between 20 certain immune cell traits and KSD, while others 11 showed a negative correlation. Additionally, immune-mediated diseases, including psoriasis, Crohn's disease, and rheumatoid arthritis, were found to increase the risk of KSD (P < 0.05, OR > 1). Finally, summary-data-based MR analysis identified HLA-C, C4A and MICA as key immune system genes in blood and kidney eQTL data. Immunofluorescence staining verified the differential expression of HLA - C and C4A in clinical RP tissues.
Indexed as
Identifiers
40498118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.